Online inquiry

IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4340MR)

This product GTTS-WQ4340MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL5RA gene. The antibody can be applied in Chronic Obstructive Pulmonary Disease (COPD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000564.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3568
UniProt ID Q01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4340MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7101MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ5876MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ1119MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ7457MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ9374MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ10079MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19TNF
GTTS-WQ2188MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ11969MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MM-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW